本文選題：高海拔地區(qū) + 勃起功能障礙�。� 參考：《中華男科學(xué)雜志》2017年10期

【摘要】：目的:探討胰激肽原酶腸溶片聯(lián)合西地那非治療高海拔地區(qū)2型糖尿病合并勃起功能障礙(ED)患者的安全性及療效。方法:選擇青海西寧地區(qū)糖尿病合并ED患者93例,隨機(jī)分成兩組,試驗組(48例)服用胰激肽原酶腸溶片(120 u,3次/d)聯(lián)合小劑量西地那非規(guī)律服用(25 mg,每晚1次),對照組(45例)小劑量西地那非規(guī)律服用(25 mg,每晚1次),兩組治療4、8周后評價兩組陰莖彩色多普勒超聲(CDDU)檢查、國際勃起功能指數(shù)(IIEF-5)、性交滿意度。結(jié)果:患者年齡及糖尿病病程兩組間均無顯著差異(P0.05)。治療4周:試驗組和對照組治療前后IIEF-5評分[(8.81±2.06)分vs(11.54±7.72)分和(8.29±1.91)分vs(9.37±1.65)分]、SIS[(3.35±2.43)分vs(6.83±2.61)分和(3.41±2.38)分vs(4.92±2.49)分]、CDDU均有顯著差異(P0.05),兩組間IIEF-5評分[(11.54±7.72)分vs(9.37±1.65)分]和SIS[(6.83±2.61)分vs(4.92±2.49)分]有顯著差異(P0.05),而CDDU參數(shù)無差異(P0.05)。治療8周:試驗組和對照組治療前后IIEF-5評分[(8.81±2.06)分vs(19.29±1.85)分和(8.29±1.91)分vs(15.43±1.74)分]均有顯著差異(P0.05),兩組間IIEF-5評分[(19.29±1.85)分vs(15.43±1.74)分]、SIS[(11.73±2.57)分vs(6.55±2.71)分]、CDDU參數(shù)均有顯著差異(P0.05)。結(jié)論:胰激肽原酶腸溶片聯(lián)合西地那非治療高海拔地區(qū)2型糖尿病合并ED患者具有一定臨床療效,且較單一西地那非治療更為有效。
[Abstract]:Objective: to investigate the safety and efficacy of pancreatic kallikrein enteric-coated tablets combined with sildenafil in the treatment of type 2 diabetes mellitus with erectile dysfunction (Ed) at high altitude. Methods: 93 diabetic patients with Ed in Xining district of Qinghai province were randomly divided into two groups. The trial group (48 cases) received pancreatic kallikinase enteric-coated tablets (120 UU / d) combined with low-dose sildenafil (25 mg once a night), the control group (45 cases) received low-dose sildenafil regularly (25 mg, once a night), and the two groups were treated for 48 weeks. After evaluation, two groups of penis color Doppler ultrasound (CDDU) were examined. International erectile function Index (IIEF-5), sexual satisfaction. Results: there was no significant difference in age and course of diabetes between the two groups (P0.05). 娌葷枟4鍛，

本文編號：2078778